SCHEMBL4835681

SCHEMBL4835681

N[C@@]1(C(=O)O)CCC[C@H](C(=O)O)C1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 8/20 0.78
GRM2 Q14416 4/20 0.78
GRM3 Q14832 4/20 0.78
CYP1A2 P05177 4/20 0.78
CYP2C19 P33261 4/20 0.78
ALOX15 P16050 3/20 0.78
TDP1 Q9NUW8 2/20 0.78
GRM8 O00222 2/20 0.78
GRM6 O15303 2/20 0.78
LMNA P02545 1/20 0.78
GRM5 P41594 1/20 0.78
MTOR P42345 1/20 0.78
GRM1 Q13255 1/20 0.78
PLCB1 Q9NQ66 1/20 0.78
TSHR P16473 1/20 0.78
ALDH1A1 P00352 2/20 0.63
KDM4E B2RXH2 1/20 0.63
ARG1 P05089 1/20 0.50
SLC6A4 P31645 1/20 0.48
MEN1 O00255 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7271016 1.00 GRM4 (0.78) GRM4GRM2GRM3CYP1A2CYP2C19
SCHEMBL2916853 1.00 GRM4 (0.78) GRM4GRM2GRM3CYP1A2CYP2C19
SCHEMBL2157698 0.88 GRM4 (1.00) GRM4GRM2GRM3CYP1A2CYP2C19
SCHEMBL935371 0.88 GRM4 (1.00) GRM4GRM2GRM3CYP1A2CYP2C19
SCHEMBL179741 0.88 GRM4 (1.00) GRM4GRM2GRM3CYP1A2CYP2C19
SCHEMBL235442 0.88 GRM4 (1.00) GRM4GRM2GRM3CYP1A2CYP2C19
SCHEMBL719389 0.88 GRM4 (1.00) GRM4GRM2GRM3CYP1A2CYP2C19
SCHEMBL4835874 0.88 GRM4 (1.00) GRM4GRM2GRM3CYP1A2CYP2C19
SCHEMBL481144 0.88 GRM4 (1.00) GRM4GRM2GRM3CYP1A2CYP2C19
SCHEMBL3125919 0.88 GRM4 (1.00) GRM4GRM2GRM3CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365091-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2008-04-29 US disclosed
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2006-12-21 US disclosed
US-7105539-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-09-12 US disclosed
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-06-22 US disclosed
EP-1572645-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX Enobia Pharma Inc. (CA) 2005-09-14 EP disclosed
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex BIOMEP INC. 2004-09-23 US disclosed
WO-2004050620-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX ENOBIA PHARMA (CA) 2004-06-17 WO disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed
US-4766110-A INHIBITS ANGIOTENSIN CONVERTING ENZYME, HYPOTENSIVE AGENTS RYAN JAMES W (US) 1988-08-23 US disclosed
EP-0073143-B1 NOVEL COMPLEX AMIDO AND IMIDO DERIVATIVES OF CARBOXYALKYL PEPTIDES AND THIOETHERS AND ETHERS OF PEPTIDES Ryan, James Walter (US) 1985-11-21 EP disclosed
EP-0073143-A2 Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides Ryan, James Walter (US) 1983-03-02 EP disclosed
EP-0048159-A2 Novel carboxyalkyl peptides and thioethers and ethers of peptides as antihypertensive agents UNIVERSITY OF MIAMI (US) 1982-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX GLS, SUCNR1, PGD GRM4 1241/4885GRM2 899/4885GRM3 1602/4885
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, PGD GRM4 1209/4885GRM2 860/4885GRM3 1620/4885
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, GCDH GRM4 1196/4885GRM2 871/4885GRM3 1656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.